7-[[4-(2,3-dichlorophenyl)piperazin-1-yl]methyl]-1H-quinolin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-[[4-(2,3-dichlorophenyl)piperazin-1-yl]methyl]-1H-quinolin-2-one
• 化学式: C₂₀H₁₉Cl₂N₃O
• 分子量: 388.3
• InChiKey: XFHJFOIFZZYLPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20140221388A1

  公开（公告）日：2014-08-07

  The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

  本发明的制药组合物包括（1）一种卡博司坦衍生物和（2）一种血清素再摄取抑制剂，以药学上可接受的载体为基础。卡博司坦衍生物可以是阿立哌唑或其代谢物，它是一种多巴胺-血清素系统稳定剂。血清素再摄取抑制剂可以是氟西汀、度洛西汀、文拉法辛、米纳西普兰、西酞普兰、氟伏沙明、帕罗西汀、舍曲林或厄贝沙丁。本发明的制药组合物对于治疗情绪障碍的患者特别是抑郁症或重度抑郁症非常有用。
• 5-HT1A RECEPTOR SUBTYPE AGONIST
  申请人：OTSUKA PHARMACEUTICAL, CO., LTD.

  公开号：US20150174125A1

  公开（公告）日：2015-06-25

  The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT 1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
• US9387182B2
  申请人：——

  公开号：US9387182B2

  公开（公告）日：2016-07-12
• US9387207B2
  申请人：——

  公开号：US9387207B2

  公开（公告）日：2016-07-12